GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (SHSE:603127) » Definitions » Cash-to-Debt

Joinn Laboratories (China) Co (SHSE:603127) Cash-to-Debt : 52.09 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Joinn Laboratories (China) Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Joinn Laboratories (China) Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 52.09.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Joinn Laboratories (China) Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Joinn Laboratories (China) Co's Cash-to-Debt or its related term are showing as below:

SHSE:603127' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.04   Med: 54.8   Max: No Debt
Current: 52.09

During the past 12 years, Joinn Laboratories (China) Co's highest Cash to Debt Ratio was No Debt. The lowest was 1.04. And the median was 54.80.

SHSE:603127's Cash-to-Debt is ranked better than
90.45% of 220 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.35 vs SHSE:603127: 52.09

Joinn Laboratories (China) Co Cash-to-Debt Historical Data

The historical data trend for Joinn Laboratories (China) Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Joinn Laboratories (China) Co Cash-to-Debt Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.78 5.94 50.72 37.91 46.62

Joinn Laboratories (China) Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.70 40.48 35.73 46.62 52.09

Competitive Comparison of Joinn Laboratories (China) Co's Cash-to-Debt

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joinn Laboratories (China) Co's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Cash-to-Debt falls into.



Joinn Laboratories (China) Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Joinn Laboratories (China) Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Joinn Laboratories (China) Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Joinn Laboratories (China) Co  (SHSE:603127) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Joinn Laboratories (China) Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co (SHSE:603127) Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Joinn Laboratories (China) Co (SHSE:603127) Headlines

No Headlines